Elsa López-Pintor1, Blanca Lumbreras. 1. Pharmacy and Pharmaceutics Division, Department of Engineering, University Miguel Hernandez, San Juan de Alicante, Alicante, Spain. elsa.lopez@umh.es
Abstract
OBJECTIVE: To assess the appropriateness of gastroprotective agents (GPA)\ NSAID use in patients' access medication through community pharmacy and the factors associated with any inappropriateness found. METHODS: A cross-sectional study in which patients requesting NSAIDs through community pharmacy was undertaken. Information was collected through a structured questionnaire included data of patients' pharmacotherapy and gastropathy risk factors. Patients were classified as "overprotected" or "underprotected" according to the use of gastroprotective-drugs and presence/absence of gastropathy risk factors. We calculated the risk for under-or over-protection using logistic regression controlling for potential confounders. RESULTS: Twenty-seven community pharmacies of Southeast of Spain participated in the study. Out of 670 NSAID users recruited in the study, 243 (36.3%) were not appropriately protected: 197(81.1%) patients were underprotected, and 46 (18.9%) patients were overprotected. Compared to patients with ulcer history, patients with cardiovascular disease or chronic morbidity (aOR 18.55; 95% CI l 3.68-93.52, P < 0.001) and aged over 60 years (aOR 23.97; 95% CI 3.93-145.9) were associated with underuse of gastroprotective-drugs. OTC-NSAID-users were more likely to be underprotected than those with medical prescription (aOR 3.47; 95% CI l 1.84-6.55). CONCLUSIONS: Inappropriate GPA use is relatively frequent among NSAD users, especially in those using OTC-NSAIDs. Community pharmacists should be aware of factors contributing to NSAID-induced GI complications and assess its presence in the consumer when dispensing an OTC-NSAID.
OBJECTIVE: To assess the appropriateness of gastroprotective agents (GPA)\ NSAID use in patients' access medication through community pharmacy and the factors associated with any inappropriateness found. METHODS: A cross-sectional study in which patients requesting NSAIDs through community pharmacy was undertaken. Information was collected through a structured questionnaire included data of patients' pharmacotherapy and gastropathy risk factors. Patients were classified as "overprotected" or "underprotected" according to the use of gastroprotective-drugs and presence/absence of gastropathy risk factors. We calculated the risk for under-or over-protection using logistic regression controlling for potential confounders. RESULTS: Twenty-seven community pharmacies of Southeast of Spain participated in the study. Out of 670 NSAID users recruited in the study, 243 (36.3%) were not appropriately protected: 197(81.1%) patients were underprotected, and 46 (18.9%) patients were overprotected. Compared to patients with ulcer history, patients with cardiovascular disease or chronic morbidity (aOR 18.55; 95% CI l 3.68-93.52, P < 0.001) and aged over 60 years (aOR 23.97; 95% CI 3.93-145.9) were associated with underuse of gastroprotective-drugs. OTC-NSAID-users were more likely to be underprotected than those with medical prescription (aOR 3.47; 95% CI l 1.84-6.55). CONCLUSIONS: Inappropriate GPA use is relatively frequent among NSAD users, especially in those using OTC-NSAIDs. Community pharmacists should be aware of factors contributing to NSAID-induced GI complications and assess its presence in the consumer when dispensing an OTC-NSAID.
Authors: F Clinard; M Bardou; C Sgro; N Lefevre; F Raphael; F Paille; M Dumas; P Hillon; C Bonithon-Kopp Journal: Eur J Clin Pharmacol Date: 2001-12 Impact factor: 2.953
Authors: Angel Lanas; Maria Angeles Perez-Aisa; Faust Feu; Julio Ponce; Esteban Saperas; Santos Santolaria; Luis Rodrigo; Joaquim Balanzo; Eduardo Bajador; Pedro Almela; Jose M Navarro; Fernando Carballo; Manuel Castro; Enrique Quintero Journal: Am J Gastroenterol Date: 2005-08 Impact factor: 10.864
Authors: Christian Roux; Karine Briot; Laure Gossec; Sami Kolta; Tilo Blenk; Dieter Felsenberg; David M Reid; Richard Eastell; Claus C Glüer Journal: Calcif Tissue Int Date: 2008-11-21 Impact factor: 4.333
Authors: Ying He; Esther W Chan; Kenneth K C Man; Wallis C Y Lau; Wai K Leung; Lai M Ho; Ian C K Wong Journal: Drug Saf Date: 2014-09 Impact factor: 5.606